← Back to all trials
Active Not Recruiting
NCT05744076
Analysis of Circulating Exosomes in Melanoma Patients
Conditions: Melanoma
Sex: All
Ages: 18 Years – N/A
Enrollment: 150
Sponsor: Centre Hospitalier Universitaire de Besancon
Location: France
Summary
The hypothesis is that PD-L1[Programmed Death-Ligand 1] labeling in exosomes could be a biomarker of disease progression in melanoma.
The rate of circulating exosomes, their size and the exosomal expression of PD-L1 could be correlated with the stage of the disease, the response to treatment and/or the prognosis of patients.
In this study, blood samples (EDTA tubes taken as part of routine care at Besançon University Hospital) and associated clinical data are reused.
Eligibility Criteria
Inclusion Criteria:Melanoma patients admitted in Besançon University Hospitalexigible for immunotherapy such as anti PD-L1/PD-1Age ≥18 yearsAffiliation to a social security system,Exclusion Criteria:Minor patientsPatients who have expressed their opposition to the reuse of their data and biological samples
Source: ClinicalTrials.gov (NCT05744076). StuddyBuddy aggregates publicly available trial information.
